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Importance—Few studies have evaluated the relationship between influenza vaccination and 
pneumonia, a serious complication of influenza infection.
Objective—Assess the association between influenza vaccination status and hospitalization for 
community-acquired laboratory-confirmed influenza pneumonia.
Design, Setting and Participants—The Etiology of Pneumonia in the Community (EPIC) 
study was a prospective observational multicenter study of hospitalizations for community-
acquired pneumonia conducted from January 2010 through June 2012 in four US sites. We used 
EPIC study data from patients ≥6 months of age with laboratory-confirmed influenza infection and 
verified vaccination status during the influenza seasons, and excluded patients with recent 
hospitalization, from chronic care residential facilities, and with severe immunosuppression. 
Logistic regression was used to calculate odds ratios, comparing the odds of vaccination between 
influenza-positive (cases) and influenza-negative (controls) pneumonia patients, controlling for 
demographics, co-morbidities, season, study site and timing of disease onset. Vaccine 
effectiveness was estimated as (1-odds ratio) × 100%.
Exposure—Influenza vaccination, verified through record review.
Outcome—Influenza pneumonia, confirmed by real-time reverse transcription-polymerase chain 
reaction performed on nasal/oropharyngeal swabs.
Results—Overall, 2767 patients hospitalized for pneumonia were eligible for the study; 162 
(5.9%) were influenza positive. Twenty-eight (17%) of 162 cases with influenza-associated 
pneumonia and 766 (29%) of 2605 controls with influenza-negative pneumonia had been 
vaccinated. The adjusted odds ratio of prior influenza vaccination between cases and controls was 
0.43 (95% CI 0.28–0.68 [estimated vaccine effectiveness 56.7% (95% CI 31.9–72.5)]).
Conclusions and relevance—Among children and adults hospitalized with community-
acquired pneumonia, those with laboratory confirmed influenza-associated pneumonia, compared 
to those with pneumonia not associated with influenza, had lower odds of having received 
influenza vaccination.
Keywords
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INTRODUCTION
Influenza remains an important cause of morbidity and mortality worldwide. In the United 
States (US), seasonal influenza epidemics are responsible for an estimated average of 
226,000 hospitalizations and between 3,000–49,000 deaths each year.1,2 Pneumonia, the 
leading infectious cause of hospitalization and death in the US, is a relatively common and 
serious complication of influenza.3
The primary strategy to reduce influenza burden is vaccination. Currently, the US Advisory 
Committee on Immunization Practices (ACIP) recommends annual influenza vaccination for 
all persons ≥6 months of age.1,2 Supporting evidence from randomized controlled trials, 
conducted mainly in outpatient settings, indicates that influenza vaccines are effective in 
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preventing influenza-associated acute respiratory illnesses among healthy children and 
adults.4,5
Vaccine effectiveness studies based on laboratory-confirmed influenza infections and 
verified vaccinations are essential to evaluate the public health value of influenza vaccines 
and to inform vaccination policies.6,7 Recent observational studies have consistently shown 
that vaccination is associated with lower odds of hospitalization for laboratory-confirmed 
influenza acute respiratory infections.3,7–14
However, whether influenza vaccines can decrease the risk of influenza associated-
hospitalizations for community-acquired pneumonia remains unclear.5,6,15 Since influenza 
vaccination is currently recommended for all persons ≥6 months old in the US, 
observational studies are the only option to assess vaccine effectiveness. We sought to 
determine whether influenza vaccination was associated with reduced odds of 
hospitalizations for laboratory-confirmed influenza-associated pneumonia.
METHODS
Study design and population
The US Centers for Disease Control and Prevention (CDC) Etiology of Pneumonia in the 
Community (EPIC) Study was conducted from January 2010 through June 2012.16,17 
Children and adults admitted with community-acquired pneumonia were enrolled at eight 
hospitals in four sites: Nashville, TN; Memphis, TN; Chicago, IL; and, Salt Lake City, UT. 
Pneumonia was defined as evidence of acute infection, symptoms of respiratory illness, and 
radiologic findings compatible with pneumonia. Patients with history of recent 
hospitalization, children who were residents of chronic care facilities, adults who were 
nursing home residents and not independently functioning (defined as score >7 in the 
Activities of Daily Living Scale18), and patients with severe immunosuppression were 
excluded.16,17 Written informed consent was obtained from all participants and/or their 
caretakers. After enrollment, research personnel collected socio-demographic characteristics 
(including interview self-reported race/ethnicity), pneumonia risk factors, and healthcare 
utilization information, including vaccination history. Since children <6 months are not 
eligible for influenza vaccination, the study was restricted to patients ≥6 months. 
Institutional Review Boards of the research sites and CDC approved the study.16,17
Laboratory confirmation of influenza virus infections
Nasopharyngeal and oropharyngeal (NP/OP) swabs were collected from each patient at 
enrollment, placed into transport medium and delivered to the site research laboratories. 
Samples were stored at −70°C and then tested in batches for influenza and other respiratory 
viruses using CDC’s real-time reverse-transcription polymerase chain reaction (RT-PCR) 
protocols.16,17 To assure integrity of the samples, the presence of human RNaseP, a 
housekeeping gene, was required for evaluable samples. Laboratory personnel conducting 
the RT-PCR testing were blinded to the patients’ vaccination status and study hypotheses.
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Cases and controls
A case was a patient hospitalized for pneumonia whose NP/OP swabs collected within 72 
hours of admission tested positive for influenza by RT-PCR with a cycle threshold value of 
<40. A control was a patient hospitalized for pneumonia who tested negative for 
influenza.3,7–14,19 Only patients with verified influenza infection status were included in the 
study.20,21
Influenza vaccination status
The study exposure was verified influenza vaccination status for the current influenza 
season. Detailed influenza vaccination history was collected in the study interview, and 
medical records were reviewed for verification. We also obtained vaccination information 
from state vaccination registries and from healthcare providers and pharmacies. Vaccination 
status included receipt of monovalent vaccines (2009–2010 season) or trivalent inactivated 
or live attenuated influenza vaccines (2010–2011 and 2011–2012 seasons). Per ACIP 
recommendations, children <9 years were considered vaccinated if they had received: 1) 
Two vaccine doses for the current influenza season, given ≥28 days apart with the second 
dose >14 days before their disease onset, or 2) One or more vaccine doses in the prior 
influenza season(s) and one dose for the current season >14 days before their disease onset. 
Children ≥9 years old and adults were considered vaccinated if they had received any 
influenza vaccine for the current season >14 days before their disease onset.1,2 Partially 
vaccinated children and patients of any age whose influenza vaccination history could not be 
verified were excluded.
Influenza seasons
To assure a proper evaluation of the association between influenza pneumonia risk and prior 
influenza vaccination, we restricted our analyses to periods of influenza activity at each site, 
based on CDC surveillance data (http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html). 
We defined the beginning of the influenza season as the first week of continuous influenza 
activity with ≥2 positive tests for influenza virus identified in each of two consecutive weeks 
by the respective regional surveillance system. The season ended on the last of two 
consecutive weeks with <2 positive tests detected per week.22 Study enrollment was 
conducted from January 2010 through June 2012, and thus included part of the 2009–2010 
season, and the complete 2010–2011 and 2011–2012 influenza seasons. See supplementary 
table 1S and figure 1S for additional details.
Statistical analyses
We examined bivariate associations between potential confounders (identified a priori) and 
verified vaccination status as well as laboratory-confirmed influenza pneumonia. Potential 
confounders included age, gender, race/ethnicity, family composition (e.g., presence of 
young or school-aged children), smoking status, insurance status, use of oxygen 
supplementation at home, timing of admission relative to disease onset, timing from 
beginning of the influenza season to admission (as the disease risk may vary during the 
seasons), the specific influenza season, and the presence of immunosuppressive conditions 
(including also cancer [except skin cancer] and human immunodeficiency virus [HIV] 
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infection [with CD4 counts ≥200/mm3]) and other chronic medical conditions associated 
with influenza-associated complications including cardiopulmonary disease, diabetes 
mellitus, chronic liver/kidney disease, and neurological disease.1–3,8
We compared the odds of influenza vaccination during the current season >14 days before 
disease onset between influenza cases and controls using a multivariable logistic regression 
model, and calculated odds ratios adjusted for relevant confounders. Influenza vaccine 
effectiveness (%) was estimated as (1-aOR) × 100,11, 12 where aOR was the adjusted odds 
ratio for influenza vaccination from the final regression model.
Planned sensitivity analyses included: 1) Inclusion of vaccination status based on self-report 
to assess the statistical effect of exposure misclassification; 2) Exclusion of the first 
influenza season (2009–2010), because our study only included part of this season; 3) 
Redefining the influenza seasons to periods with either at least 4% or 5% of test positive 
samples detected in surveillance systems, to evaluate the sensitivity of our estimates to the 
influenza season definition; 4) Restriction to cases and controls hospitalized within 7 and 14 
days of symptom onset, to address concerns that influenza may be a concurrent infection and 
not the cause of pneumonia in patients with longer duration of symptoms prior to 
presentation;20,21 5) Restriction to patients with radiologic evidence of alveolar 
consolidation, infiltrate or pleural effusion, as determined by independent study radiologists, 
a common endpoint in pneumonia studies;23 6) Considering patients who tested negative for 
influenza but positive for other non-influenza viruses (including coronaviruses 229E, 
HKU1, NL63, and OC43; human metapneumovirus; human rhinovirus; parainfluenza 
viruses 1,2,3; and respiratory syncytial virus), and those patients who tested negative for all 
study viruses as alternate controls, to assess the hypothesis that influenza vaccination may 
increase the risk of non-influenza viral infections,24,25 including pneumonia, and to assess 
potential differential detection of respiratory viruses;20,21,25–27 7) Exclusion of patients who 
reported use of influenza antivirals prior to admission, as such use may interfere with RT-
PCR detection of influenza infections;28 8) Reanalyzing our data adjusting for propensity 
scores3,8 created using variables from the main analysis and 16 additional variables for 
specific comorbidities, to address concerns about residual confounding; and, 9) Using 
respiratory syncytial virus associated-pneumonia as cases and excluding all influenza cases, 
to assess the specificity of the main findings.
Subgroup analyses included estimations by age group, presence of immunosuppressive and 
chronic conditions, study site and influenza season. For these subgroups analyses, 
interaction terms between subgroup and vaccination status were examined. Estimates for 
each subgroup were calculated using linear combinations of coefficients from the regression 
models that included the interaction terms. Separate exploratory analyses for influenza type/
subtype, and influenza cases with and without co-detection of other pathogens16 were also 
conducted.
All reported tests were 2-sided and a p value <0.05 was considered significant. Statistical 
analyses were conducted in Stata 13.1 and R 3.0.2.
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RESULTS
Study population
Forty-six percent of patients enrolled in the EPIC study (n=5109) were excluded for the 
following reasons: age <6 months (n=342, 7%), enrollment outside of the influenza season 
(714, 14%), children with partial vaccination (300, 6%), vaccination within 14 days of 
disease onset (115, 2%), self-reported vaccination (518, 10%), self-reported vaccination 
with unknown vaccination date (52, 1%), unknown vaccination status (210, 4%) and 
unknown influenza infection status (91, 2%). After exclusions, 2767 patients were included 
in this study (Figure 1).
One hundred sixty-two of 2767 pneumonia patients tested positive for influenza (5.9%) by 
RT-PCR and were defined as cases, including 62 (38%) with A(H1N1)pdm09, 51 (31%) 
with A(H3N2), 43 (27%) with influenza B, 4 with influenza A with no available subtype 
information (3%) and 2 co-infections with influenza A and B (1%). Among 162 influenza 
cases, 116 cases had only influenza viruses detected, 32 had a viral co-detection and 14 had 
a bacterial co-detection. A total of 2605 controls were identified for comparison, including 
1196 controls that tested positive for other respiratory viruses and 1409 controls that tested 
negative for all viruses tested.
Characteristics of cases and controls
Compared with influenza-negative controls, influenza-positive cases had similar age 
distribution but were more likely to be black and enrolled during the 2010–2011 influenza 
season. The distribution of influenza cases differed by study site. The prevalence of 
congenital heart disease and heart failure was higher among controls. Relative to cases, 
controls were admitted earlier during the influenza seasons. The distribution of other socio-
demographic factors and co-morbidities was generally similar in both groups (Tables 1 and 
2). There were 2 (1%) in-hospital deaths among cases, and 29 (1%) among controls.
Characteristics of vaccinated and unvaccinated patients with pneumonia
A total of 794 (29%) patients with pneumonia were vaccinated during current influenza 
seasons. Compared with unvaccinated patients, vaccinated patients were older, more likely 
to be white and enrolled during the 2010–2011 influenza season. The prevalence of 
influenza vaccination differed by study research site. The prevalence of current smoking was 
lower among vaccinated patients, although they were more likely to be past smokers and 
require home oxygen supplementation. The prevalence of chronic obstructive pulmonary 
disease (COPD), cardiovascular diseases, diabetes and other chronic medical conditions was 
generally higher among vaccinated than unvaccinated patients. Unvaccinated patients were 
admitted earlier than vaccinated patients during the respective influenza seasons (Tables 1 & 
2). There were 11 (1%) in-hospital deaths among vaccinated patients, and 20 (1%) among 
unvaccinated patients. See supplementary tables 2S and 3S for additional details.
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Association between prior influenza vaccination and hospitalization for influenza-
associated pneumonia
Of 162 influenza-associated pneumonia cases, 28 (17%) were vaccinated compared with 
766 (29%) of 2605 influenza-negative controls. The adjusted odds ratio comparing the odds 
of prior vaccination among those with influenza-positive pneumonia (cases) with the odds of 
prior vaccination among those with influenza-negative pneumonia (controls) was 0.43 (95% 
CI 0.28–0.68 [estimated vaccine effectiveness 56.7% (31.9%-72.5%)]). See supplementary 
table 4S for additional details.
Results from sensitivity analyses that evaluated key study definitions and assumptions were 
similar to the main findings. There was no association between influenza vaccination and 
respiratory syncytial virus-pneumonia (Table 3).
In subgroup analyses, 7 (10%) of 68 children cases were vaccinated compared with 376 
(29%) of 1309 control children (adjusted odds ratio 0.25; 95% CI 0.11–0.58); whereas 
among adults, 21 (22%) of 94 cases were vaccinated compared with 390 (30%) of 1296 
controls (adjusted odds ratio 0.59, 95% CI 0.34–1.02). Among children 0.5–4 years old, 3 
(8%) of 40 cases and 266 (31%) of 850 controls were vaccinated, (adjusted odds ratio 0.16, 
95% CI 0.05–0.53). Among older children and adults, the differences in vaccination 
between cases and controls were more modest. Among patients without 
immunosuppression, 13 (10%) of 147 cases were vaccinated compared with 592 (27%) of 
2212 controls; whereas, among patients with immunosuppression, 15 (54%) of 28 cases 
were vaccinated compared with 174 (44%) of 393 controls. The adjusted odds ratio of prior 
vaccination between cases and controls was significantly lower among patients without 
immunosuppression (0.27; 95% CI: 0.15–0.49) compared with patients with 
immunosuppression (1.22; 95% CI: 0.55–2.71). Influenza vaccination was higher among 
patients with chronic diseases than among those without, and in both groups, vaccination in 
cases was lower than vaccination in controls (adjusted odds ratio point estimates 0.54 and 
0.24, respectively). Differences in vaccination by site likely reflected the age of the study 
populations at the sites, and the adjusted odds ratios point estimates ranged from 0.26 to 
0.50 across sites. In each of the two complete study influenza seasons, 2010–2011 and 
2011–2012, vaccination was lower among cases than among controls, and the odds ratio 
point estimate was 0.44 for both seasons. However, some subgroup analyses had limited 
precision due to small numbers (Table 4). In separate analyses that evaluated influenza 
pneumonia cases with and without co-pathogen detections, the odds ratio of vaccination 
between cases and controls was 0.43 (95% CI: 0.25–0.73) and 0.42 (95% CI: 0.18–0.99), 
respectively.
In separate assessments, the odds ratio of vaccination between cases and controls was 0.41 
(95% CI: 0.19–0.87) for influenza A(H1N1)pdm09, 0.55 (95% CI: 0.28–1.09) for influenza 
A(H3N2), and 0.28 (95% CI: 0.09–0.83) for influenza B (Table 4).
DISCUSSION
Our findings indicate that the odds of influenza vaccination among cases hospitalized with 
influenza-associated pneumonia was lower than among non-influenza pneumonia controls, 
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with an adjusted odds ratio of 0.43 (95% CI 0.28–0.68 [estimated vaccine effectiveness 
56.7%]) during 2009–2012 influenza seasons. This large multi-center study addressed 
several concerns identified in previous influenza vaccine effectiveness assessments. By 
performing systematic influenza testing for all patients with pneumonia, our study relied on 
an unbiased sample of laboratory-confirmed influenza-pneumonia hospitalizations. Our 
patients with pneumonia were prospectively identified, minimizing concerns about outcome 
misclassification. To assure a proper evaluation of the association between influenza 
pneumonia risk and prior influenza vaccination, the study was restricted to influenza seasons 
and to patients with similar propensity to require hospital care. Furthermore, vaccination 
information was actively collected, and only patients with pneumonia and verified influenza 
vaccination history were included in our main analyses.
Previous studies that used a similar design have shown that influenza vaccination is effective 
in preventing hospitalizations for acute respiratory illnesses associated with laboratory-
confirmed influenza.3,7–14 Although some studies had limited precision, the point estimates 
of effectiveness ranged from 53% to 67% among children,10,11 from 54% to 71% among all 
adults,3,12 and from 42% to 61% among adults 65 years or older.8,13 However, few studies 
have examined the effectiveness of influenza vaccination in preventing complications of 
influenza infections, such as pneumonia. In a recent multinational randomized controlled 
trial of a new quadrivalent inactivated influenza vaccine in children 3–8 years old, a post-
hoc analysis of influenza-associated lower respiratory tract illness alone yielded a vaccine 
efficacy estimate of approximately 80%.29 Likewise, a recent case-control study estimated 
that influenza vaccination was associated with a 74% reduction in the odds of pediatric 
intensive care units admission during the 2010–2012 seasons.30
Although previous studies focusing on the prevention of all-cause pneumonia have 
suggested a modest effectiveness of influenza vaccines,15,31 using all-cause pneumonia as 
the outcome for influenza vaccine effectiveness assessments is problematic because 
influenza is responsible for only a fraction of all pneumonias and varies seasonally, resulting 
in an underestimation of the true vaccine effectiveness.6,20,21,32 Our study avoided this 
misclassification by applying a prospective and systematic approach for confirming 
influenza infections and a standardized definition of hospitalizations for pneumonia. The 
estimated odds ratio of vaccination between cases and controls, and derived vaccine 
effectiveness from this study, could be used to inform subsequent estimations of the national 
number of hospitalizations for pneumonia averted by influenza vaccination.33
Findings from our subgroup analyses suggest that the odds ratio of prior influenza 
vaccination between cases and controls was higher in patients with immunosuppressive 
conditions, including cancers and HIV infection, suggesting lower vaccine effectiveness. 
Although several studies have described reduced immunogenicity of influenza vaccines in 
immunosuppressed patients, few have evaluated the vaccine effectiveness in preventing 
influenza pneumonia in patients with these conditions. A small, open label randomized 
controlled trial of influenza vaccination among patients with multiple myeloma reported a 
non-significant reduction in all-cause pneumonia, but the number of events was small and 
the study included only one season.34 Other observational influenza vaccine effectiveness 
studies have reported reductions in all-cause pneumonia in patients with immunosuppressive 
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conditions; but these events were not confirmed influenza infections.35 Evidence for the 
effectiveness of influenza vaccines in preventing pneumonia among patients with HIV 
infection is also limited.36 While these findings warrant replication in other settings, they 
highlight the vulnerability of older adults and patients with immunosuppressive conditions, 
and the need for additional measures to reduce their risk of influenza infection and related 
complications.
One concern with observational studies of influenza-associated hospitalizations is the 
control of unmeasured or poorly measured confounding factors, such as disease severity or 
baseline characteristics that increase the likelihood that pneumonia will require 
hospitalization. For example, retrospective studies of influenza vaccination and all-cause 
mortality have reported that indicators of poor functional status are relevant confounders 
because they are associated with both likelihood of not being vaccinated and risk of death, 
but are rarely considered.37 Our study used a test-positive case test-negative control design, 
a design widely used for vaccine effectiveness assessments that has been shown to be 
superior to case-control studies of hospitalized cases with population controls, since the 
likelihood of hospitalization is implicitly accounted for.20,21 In addition, our study excluded 
nursing home residents with limited functional status and prospectively gathered 
information on risk factors for pneumonia.20,38,39
Our findings must be interpreted in light of several limitations. First, although we conducted 
an extensive evaluation of potential threats to the validity of our estimates, our observational 
design is vulnerable to some misclassification and residual confounding. Nevertheless, the 
use of a well-established design, and the consistency of findings in a number of pre-
specified sensitivity analyses conducted to evaluate key assumptions should help allay these 
concerns. Second, despite enrollment over three consecutive seasons, a relatively small 
number of influenza-associated pneumonia cases met eligibility criteria, resulting in limited 
precision for some subgroup analyses. Thus, the association between influenza vaccines and 
pneumonia in older adults remains controversial, and additional studies in this group are 
needed.2,5,7 Although there are different types of vaccines available and some ecological 
evidence suggest that influenza A(H3N2) strains are associated with higher pneumonia 
mortality,40 more detailed assessments by vaccine type, specific influenza types/subtypes or 
history of previous vaccination were not possible. Third, patients missing verified 
vaccination status were excluded from our main analysis. However, a sensitivity analysis 
showed that including patients with un-verified but self-reported vaccination information 
likely introduced misclassification and diluted the observed association. If influenza cases 
that were excluded because of unknown vaccination were indeed not vaccinated, then our 
findings could have overestimated the true odds ratios (and underestimated the vaccine 
effectiveness). Fourth, while our study comprised a diverse population, it only included four 
US geographical areas, which may prevent direct extrapolation of our findings to other 
settings. Fifth, our study included only a few influenza seasons during which vaccine strains 
were generally well matched with the circulating influenza strains.40 Sixth, we acknowledge 
that it is possible that some pneumonia cases were secondary to an earlier influenza 
infection that could have been missed by our tests. However, this concern is attenuated since 
the median time from disease onset to hospitalization was only 3 days. Finally, our study 
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focused on pneumonia hospitalizations only, and additional studies in the ambulatory setting 
would be useful to complement these findings.2,7
Conclusion
Among children and adults hospitalized with community-acquired pneumonia, those with 
laboratory confirmed influenza-associated pneumonia, compared to those with pneumonia 
not associated with influenza, had lower odds of having received influenza vaccination.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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FIGURE 1. Patient flow chart in study
Footnote: Research sites B and D enrolled only children, site A enrolled only adults and site 
C enrolled both children and adults; *Influenza infection status could not be determined in 
91 patients (1.8% of total enrolled), including patients without samples available for testing 
and patients with samples collected after 72 hours of admission or with missing data on the 
time of sample collection.
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TABLE 3
Sensitivity Analyses
Sensitivity Analyses Vaccinated /
Cases (%)
Vaccinated /
Controls (%)
Adjusted Odds
Ratio (95% CI)
Estimated vaccine
effectiveness (95% 
CI)
Overall estimate 28 / 162 (17%) 766 / 2605 (29%) 0.43 (0.28, 0.68) 56.7 (31.9, 72.5)
Including self-reported vaccination 56 / 190 (29%) 1241 / 3270 (38%) 0.52 (0.37, 0.75) 47.5 (25.3, 63.2)
Influenza season defined using >4% positive tests per 
week
28 / 154 (18%) 579 / 1563 (37%) 0.41 (0.26, 0.65) 59.1 (35.3, 74.1)
Influenza season defined using >5% positive tests per 
week
28 / 153 (18%) 523 / 1458 (36%) 0.40 (0.25, 0.63) 60.1 (36.8, 74.8)
Season 2010–2012 28 / 156 (18%) 721 / 2300 (31%) 0.44 (0.28, 0.69) 56.4 (31.2, 72.3)
Restricted to 7 days of symptoms onset 23 / 136 (17%) 624 / 2071 (30%) 0.41 (0.25, 0.68) 58.9 (32.3, 75.0)
Restricted to 14 days of symptoms onset 26 / 154 (17%) 710 / 2379 (30%) 0.43 (0.27, 0.68) 57.3 (31.7, 73.2)
Restricted to radiographic consolidation or pleural 
effusion
24 / 139 (17%) 700 / 2389 (29%) 0.43 (0.27, 0.71) 56.6 (29.2, 73.4)
Use of influenza (−), other virus (+) as controls 28 / 162 (17%) 368 / 1196 (31%) 0.37 (0.23, 0.61) 62.8 (39.5, 77.1)
Use of influenza (−), other virus (−) as controls 28 / 162 (17%) 398 / 1409 (28%) 0.46 (0.29, 0.74) 53.8 (25.5, 71.4)
Exclude subjects with previous use of antivirals 27 / 155 (17%) 750 / 2546 (29%) 0.44 (0.28, 0.70) 56.2 (30.4, 72.4)
Propensity score-adjusted analysis 28 / 162 (17%) 766 / 2605 (29%) 0.45 (0.29, 0.72) 54.9 (28.5, 71.5)
Use of respiratory syncytial virus-pneumonia as cases 125 / 396 (32%) 641 / 2209 (29%) 1.18 (0.88, 1.58)* −18.0 (−57.6, 11.7)
Footnote: Vaccine effectiveness was estimated as (1-adjusted odds ratios) × 100; where odds ratios compared the odds of vaccination between 
cases and controls while controlling for age, gender, race/ethnicity, presence of children at home, smoking status, insurance status, use of oxygen 
supplementation at home, timing of admission relative to disease onset, timing from beginning of the influenza season to admission, the specific 
influenza season, and the presence of immunosuppressive conditions and other chronic medical conditions associated with influenza-associated 
complications including cardiopulmonary disease, diabetes mellitus, chronic liver/kidney disease, and neurological disease. Sensitivity analyses 
included: inclusion of self-reported vaccination data; influenza seasons defined as having at least 4% or 5% positive influenza tests per week; 
restriction to complete seasons 2010–2011 & 2011–2012; restriction to hospitalizations within 7 & 14 days of disease onset; restriction to patients 
with independent radiologic assessment indicating consolidation, infiltrate or pleural effusion; defining control pneumonia patients as those who 
were influenza negative but tested positive for other respiratory viruses; defining control pneumonia patients as those who tested negative for all 
respiratory viruses; excluding patients with any antiviral use before admission; propensity score-adjusted analysis included 16 additional variables 
for individual chronic medical conditions; and, a separate analysis that evaluated the association between influenza vaccination and respiratory 
syncytial virus-pneumonia.
*Although this odds ratio was not statistically different from 1, the point-estimate odds ratio greater than 1 (and the corresponding negative vaccine 
effectiveness point-estimate) indicates that the odds of vaccination among cases was numerically higher than the odds of vaccination among 
controls.
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TABLE 4
Subgroup analyses
Subgroups Vaccinated /
Cases (%)
Vaccinated /
Controls (%)
Adjusted Odds Ratio
(95% CI)
Estimated vaccine
effectiveness (95% CI)
Overall Estimate 28 / 162 (17%) 766 / 2605 (29%) 0.43 (0.28, 0.68) 56.7 (31.9, 72.5)
Groups (p=0.096)
  Children 7 / 68 (10%) 376 / 1309 (29%) 0.25 (0.11, 0.58) 74.6 (42.5, 88.8)
  Adults 21 / 94 (22%) 390 / 1296 (30%) 0.59 (0.34, 1.02) 41.5 (−2.2, 66.5)
Age groups (p=0.412)
  Age 0.5–4 years 3 / 40 (8%) 266 / 850 (31%) 0.16 (0.05, 0.53) 84.3 (47.3, 95.3)
  Age 5–17 years 4 / 28 (14%) 110 / 459 (24%) 0.48 (0.16, 1.44) 52.4 (−43.5, 84.2)
  Age 18–49 years 4 / 36 (11%) 76 / 433 (18%) 0.57 (0.19, 1.73) 43.1 (−72.5, 81.2)
  Age 50–64 years 9 / 38 (24%) 122 / 354 (34%) 0.66 (0.29, 1.50) 33.9 (−49.7, 70.8)
  Age 65+ years 8 / 20 (40%) 192 / 409 (47%) 0.52 (0.20, 1.33) 48.4 (−33.3, 80)
Immunosuppression (p=0.003)
  No 13 / 134 (10%) 592 / 2212 (27%) 0.27 (0.14, 0.49) 73.4 (51.1, 85.5)
  Yes 15 / 28 (54%) 174 / 393 (44%) 1.22 (0.55, 2.71)£ −21.9 (−170.7, 45.1)
Chronic Diseases (p=0.141)
  No 5 / 71 (7%) 229 / 977 (23%) 0.24 (0.09, 0.62) 75.7 (37.6, 90.6)
  Yes 23 / 91 (25%) 537 / 1628 (33%) 0.54 (0.32, 0.91) 45.9 (8.6, 67.9)
Research Sites (p=0.825)
  A* 11 / 63 (17%) 182 / 717 (25%) 0.49 (0.24, 1.02) 51.1 (−1.56, 76.41)
  B** 2 / 38 (5%) 83 / 544 (15%) 0.26 (0.06, 1.10) 74.2 (−10.5, 94)
  C 12 / 46 (26%) 387 / 1017 (38%) 0.50 (0.25, 0.99) 50.5 (1.1, 75.3)
  D** 3 / 15 (20%) 114 / 327 (35%) 0.33 (0.09, 1.21) 67.2 (−20.8, 91.1)
Influenza Seasons*** (p=0.981)
  Season 2010–2011 18 / 97 (19%) 408 / 1283 (32%) 0.44 (0.25, 0.77) 55.9 (22.5, 74.8)
  Season 2011–2012 10 / 59 (17%) 313 / 1017 (31%) 0.44 (0.22, 0.90) 55.9 (9.8, 78.4)
Virus type/subtype****
  A(H1N1)pdm09 9 / 62 (15%) 766 / 2605 (29%) 0.40 (0.19, 0.87) 59.5 (13.0, 81.2)
  A(H3N2) 14 / 51 (27%) 766 / 2605 (29%) 0.55 (0.28, 1.09) 45.1 (−9.3, 72.4)
  B 4 / 43 (9%) 766 / 2605 (29%) 0.28 (0.09, 0.83) 72.0 (16.8, 90.6)
Footnote: Vaccine effectiveness was estimated as (1-adjusted odds ratios)*100; where odds ratios compared the odds of vaccination between cases 
and controls while controlling for age, gender, race/ethnicity, presence of children at home, smoking status, insurance status, use of oxygen 
supplementation at home, timing of admission relative to disease onset, timing from beginning of the influenza season to admission, the specific 
influenza season, and the presence of immunosuppressive conditions and other chronic medical conditions associated with influenza-associated 
complications including cardiopulmonary disease, diabetes mellitus, chronic liver/kidney disease, and neurological disease.
£Although this odds ratio was not statistically different from 1, the point-estimate odds ratio greater than 1 (and the corresponding negative vaccine 
effectiveness point-estimate) indicates that the odds of vaccination among cases was numerically higher than the odds of vaccination among 
controls.
*Adult only site;
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**Children only site;
***
Estimates for season 2009–2010 could not be calculated separately because there were no vaccinated subjects among the influenza cases;
****Separate estimates were conducted for influenza virus type/subtype. Reported p values correspond to the interaction term between subgroup 
and vaccination status. Subgroup estimates were calculated using linear combinations of coefficients from the regression models that included the 
interaction terms.
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